OBJECTIVE: Preclinical and genetic epidemiologic studies suggest that modulating cytochrome P450 (CYP)-mediated arachidonic acid metabolism may have therapeutic utility in the management of coronary artery disease (CAD). However, predictors of inter-individual variation in CYP-derived eicosanoid metabolites in CAD patients have not been evaluated to date. Therefore, the primary objective was to identify clinical factors that influence CYP epoxygenase, soluble epoxide hydrolase (sEH), and CYP ω-hydroxylase metabolism in patients with established CAD. METHODS: Plasma levels of epoxyeicosatrienoic acids (EETs), dihydroxyeicosatrienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE) were quantified by HPLC-MS/MS in a population of patients with stable, angiographically confirmed CAD (N=82) and healthy volunteers from the local community (N=36). Predictors of CYP epoxygenase, sEH, and CYP ω-hydroxylase metabolic function were evaluated by regression. RESULTS: Obesity was significantly associated with low plasma EET levels and 14,15-EET:14,15-DHET ratios. Age, diabetes, and cigarette smoking also were significantly associated with CYP epoxygenase and sEH metabolic activity, while only renin-angiotensin system inhibitor use was associated with CYP ω-hydroxylase metabolic activity. Compared to healthy volunteers, both obese and non-obese CAD patients had significantly higher plasma EETs (P<0.01) and epoxide:diol ratios (P<0.01), whereas no difference in 20-HETE levels was observed (P=NS). CONCLUSIONS: Collectively, these findings suggest that CYP-mediated eicosanoid metabolism is dysregulated in certain subsets of CAD patients, and demonstrate that biomarkers of CYP epoxygenase and sEH, but not CYP ω-hydroxylase, metabolism are altered in stable CAD patients relative to healthy individuals. Future studies are necessary to determine the therapeutic utility of modulating these pathways in patients with CAD.
OBJECTIVE: Preclinical and genetic epidemiologic studies suggest that modulating cytochrome P450 (CYP)-mediated arachidonic acid metabolism may have therapeutic utility in the management of coronary artery disease (CAD). However, predictors of inter-individual variation in CYP-derived eicosanoid metabolites in CAD patients have not been evaluated to date. Therefore, the primary objective was to identify clinical factors that influence CYP epoxygenase, soluble epoxide hydrolase (sEH), and CYP ω-hydroxylase metabolism in patients with established CAD. METHODS: Plasma levels of epoxyeicosatrienoic acids (EETs), dihydroxyeicosatrienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE) were quantified by HPLC-MS/MS in a population of patients with stable, angiographically confirmed CAD (N=82) and healthy volunteers from the local community (N=36). Predictors of CYP epoxygenase, sEH, and CYP ω-hydroxylase metabolic function were evaluated by regression. RESULTS: Obesity was significantly associated with low plasma EET levels and 14,15-EET:14,15-DHET ratios. Age, diabetes, and cigarette smoking also were significantly associated with CYP epoxygenase and sEH metabolic activity, while only renin-angiotensin system inhibitor use was associated with CYP ω-hydroxylase metabolic activity. Compared to healthy volunteers, both obese and non-obese CAD patients had significantly higher plasma EETs (P<0.01) and epoxide:diol ratios (P<0.01), whereas no difference in 20-HETE levels was observed (P=NS). CONCLUSIONS: Collectively, these findings suggest that CYP-mediated eicosanoid metabolism is dysregulated in certain subsets of CAD patients, and demonstrate that biomarkers of CYP epoxygenase and sEH, but not CYP ω-hydroxylase, metabolism are altered in stable CAD patients relative to healthy individuals. Future studies are necessary to determine the therapeutic utility of modulating these pathways in patients with CAD.
Authors: Kasem Nithipatikom; Eric R Gross; Michael P Endsley; Jeannine M Moore; Marilyn A Isbell; John R Falck; William B Campbell; Garrett J Gross Journal: Circ Res Date: 2004-09-23 Impact factor: 17.367
Authors: Dawn Chen; Randall Whitcomb; Euan MacIntyre; Vinh Tran; Zung N Do; James Sabry; Dinesh V Patel; Sampath K Anandan; Richard Gless; Heather K Webb Journal: J Clin Pharmacol Date: 2011-03-21 Impact factor: 3.126
Authors: Craig R Lee; Kari E North; Molly S Bray; Myriam Fornage; John M Seubert; John W Newman; Bruce D Hammock; David J Couper; Gerardo Heiss; Darryl C Zeldin Journal: Hum Mol Genet Date: 2006-04-04 Impact factor: 6.150
Authors: Katherine N Theken; Yangmei Deng; Robert N Schuck; Akinyemi Oni-Orisan; Tricia M Miller; M Alison Kannon; Samuel M Poloyac; Craig R Lee Journal: Am J Physiol Endocrinol Metab Date: 2011-12-20 Impact factor: 4.310
Authors: Cheng-Chia Wu; Jennifer Cheng; Frank Fan Zhang; Katherine H Gotlinger; Mukul Kelkar; Yilun Zhang; Jawahar L Jat; John R Falck; Michal L Schwartzman Journal: Hypertension Date: 2011-02-14 Impact factor: 10.190
Authors: Natalie C Ward; Jennifer Rivera; Jonathan Hodgson; Ian B Puddey; Lawrie J Beilin; John R Falck; Kevin D Croft Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Jan Monti; Judith Fischer; Svetlana Paskas; Matthias Heinig; Herbert Schulz; Claudia Gösele; Arnd Heuser; Robert Fischer; Cosima Schmidt; Alexander Schirdewan; Volkmar Gross; Oliver Hummel; Henrike Maatz; Giannino Patone; Kathrin Saar; Martin Vingron; Steven M Weldon; Klaus Lindpaintner; Bruce D Hammock; Klaus Rohde; Rainer Dietz; Stuart A Cook; Wolf-Hagen Schunck; Friedrich C Luft; Norbert Hubner Journal: Nat Genet Date: 2008-05 Impact factor: 38.330
Authors: Craig R Lee; John D Imig; Matthew L Edin; Julie Foley; Laura M DeGraff; J Alyce Bradbury; Joan P Graves; Fred B Lih; James Clark; Page Myers; A Ligon Perrow; Adrienne N Lepp; M Alison Kannon; Oline K Ronnekleiv; Nabil J Alkayed; John R Falck; Kenneth B Tomer; Darryl C Zeldin Journal: FASEB J Date: 2010-05-21 Impact factor: 5.191
Authors: Albert W Dreisbach; Stanley V Smith; Patrick B Kyle; Manjunath Ramaiah; Margaret Amenuke; Michael R Garrett; Seth T Lirette; Michael E Griswold; Richard J Roman Journal: Prostaglandins Other Lipid Mediat Date: 2014-08-22 Impact factor: 3.072
Authors: Darko Stefanovski; Pei-An Betty Shih; Bruce D Hammock; Richard M Watanabe; Jang H Youn Journal: Prostaglandins Other Lipid Mediat Date: 2020-01-10 Impact factor: 3.072
Authors: Yossi Issan; Edith Hochhauser; Austin Guo; Katherine H Gotlinger; Ran Kornowski; Dorit Leshem-Lev; Eli Lev; Eyal Porat; Eitan Snir; Carl I Thompson; Nader G Abraham; Michal Laniado-Schwartzman Journal: Prostaglandins Other Lipid Mediat Date: 2013-01-03 Impact factor: 3.072
Authors: V Lamounier-Zepter; C Look; W-H Schunck; I Schlottmann; C Woischwill; S R Bornstein; A Xu; I Morano Journal: Int J Obes (Lond) Date: 2014-11-05 Impact factor: 5.095
Authors: Naoto Fujii; Maggie C Reinke; Vienna E Brunt; Christopher T Minson Journal: Am J Physiol Heart Circ Physiol Date: 2013-01-11 Impact factor: 4.733
Authors: Arash Mohebati; Ginger L Milne; Xi Kathy Zhou; Anna J Duffield-Lillico; Jay O Boyle; Allison Knutson; Brian P Bosworth; Philip J Kingsley; Lawrence J Marnett; Powel H Brown; Esther G Akpa; Eva Szabo; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2013-05-16
Authors: Claudia E Ramirez; Megan M Shuey; Ginger L Milne; Kimberly Gilbert; Nian Hui; Chang Yu; James M Luther; Nancy J Brown Journal: Prostaglandins Other Lipid Mediat Date: 2014-08-28 Impact factor: 3.072